106 related articles for article (PubMed ID: 23093489)
1. Effects of recombinant follicle-stimulating hormone on bone turnover markers in infertile women undergoing in vitro fertilization procedure.
Omodei U; Mazziotti G; Donarini G; Gola M; Guella V; Pagani F; Bugari G; Porcelli T; Giustina A
J Clin Endocrinol Metab; 2013 Jan; 98(1):330-6. PubMed ID: 23093489
[TBL] [Abstract][Full Text] [Related]
2. Increased adiposity enhances intrafollicular estradiol levels in normoandrogenic ovulatory women receiving gonadotropin-releasing hormone analog/recombinant human follicle-stimulating hormone therapy for in vitro fertilization.
Dumesic DA; Lesnick TG; Abbott DH
J Clin Endocrinol Metab; 2007 Apr; 92(4):1438-41. PubMed ID: 17244784
[TBL] [Abstract][Full Text] [Related]
3. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer.
Propst AM; Bates GW; Robinson RD; Arthur NJ; Martin JE; Neal GS
Fertil Steril; 2006 Jul; 86(1):58-63. PubMed ID: 16753156
[TBL] [Abstract][Full Text] [Related]
4. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
[TBL] [Abstract][Full Text] [Related]
5. Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing hormone agonist and stimulated with recombinant follicle-stimulating hormone.
Cabrera RA; Stadtmauer L; Mayer JF; Gibbons WE; Oehninger S
Fertil Steril; 2005 Jan; 83(1):42-8. PubMed ID: 15652885
[TBL] [Abstract][Full Text] [Related]
6. Elevated day 3 follicle-stimulating hormone in younger women: is gonadotropin stimulation/intrauterine insemination a good option?
Souter I; Dimitriadis I; Baltagi LM; Meeker JD; Petrozza JC
Am J Obstet Gynecol; 2014 Jul; 211(1):62.e1-8. PubMed ID: 24487006
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of mixed protocols with Bravelle (human-derived FSH) and Repronex (hMG) to assess clinical efficacy (EMBRACE) in women undergoing in vitro fertilization.
Keye WR; Marrs RP; Check JH; Schnell V; Surrey M; Marshall DC;
Fertil Steril; 2004 Aug; 82(2):348-57. PubMed ID: 15302283
[TBL] [Abstract][Full Text] [Related]
8. Effects of intranasal 17beta-estradiol on bone turnover and serum insulin-like growth factor I in postmenopausal women.
Garnero P; Tsouderos Y; Marton I; Pelissier C; Varin C; Delmas PD
J Clin Endocrinol Metab; 1999 Jul; 84(7):2390-7. PubMed ID: 10404809
[TBL] [Abstract][Full Text] [Related]
9. Determinants of bone turnover markers in healthy premenopausal women.
Adami S; Bianchi G; Brandi ML; Giannini S; Ortolani S; DiMunno O; Frediani B; Rossini M;
Calcif Tissue Int; 2008 May; 82(5):341-7. PubMed ID: 18470550
[TBL] [Abstract][Full Text] [Related]
10. Induction of multiple follicular development by a single dose of long-acting recombinant follicle-Stimulating hormone (FSH-CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization.
Devroey P; Fauser BC; Platteau P; Beckers NG; Dhont M; Mannaerts BM
J Clin Endocrinol Metab; 2004 May; 89(5):2062-70. PubMed ID: 15126522
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of recombinant human follicle-stimulating hormone in improving oocyte quality in assisted reproductive techniques.
Cheon KW; Byun HK; Yang KM; Song IO; Choi KH; Yoo KJ
J Reprod Med; 2004 Sep; 49(9):733-8. PubMed ID: 15493565
[TBL] [Abstract][Full Text] [Related]
12. Recombinant FSH vs. urinary FSH for ovarian stimulation in in vitro fertilization.
Meden-Vrtovec H; Mocnik-Roznik S; Tomazevic T; Virant-Klun I
J Reprod Med; 2003 Oct; 48(10):799-803. PubMed ID: 14619648
[TBL] [Abstract][Full Text] [Related]
13. Outcome of in vitro fertilization following stimulation with highly purified hMG or recombinant FSH in downregulated women of advanced reproductive age: a prospective, randomized and controlled trial.
Ye H; Huang G; Pei L; Zeng P; Luo X
Gynecol Endocrinol; 2012 Jul; 28(7):540-4. PubMed ID: 22390186
[TBL] [Abstract][Full Text] [Related]
14. Diminished intrafollicular estradiol levels in in vitro fertilization cycles from women with reduced ovarian response to recombinant human follicle-stimulating hormone.
Foong SC; Abbott DH; Lesnick TG; Session DR; Walker DL; Dumesic DA
Fertil Steril; 2005 May; 83(5):1377-83. PubMed ID: 15866572
[TBL] [Abstract][Full Text] [Related]
15. Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
Fatemi HM; Polyzos NP; van Vaerenbergh I; Bourgain C; Blockeel C; Alsbjerg B; Papanikolaou EG; Humaidan P
Fertil Steril; 2013 Sep; 100(3):742-7. PubMed ID: 23806846
[TBL] [Abstract][Full Text] [Related]
16. The relationship between luteinizing hormone and estradiol secretion in female precocious puberty: evaluation by sensitive gonadotropin assays and the leuprolide stimulation test.
Garibaldi LR; Aceto T; Weber C; Pang S
J Clin Endocrinol Metab; 1993 Apr; 76(4):851-6. PubMed ID: 8473395
[TBL] [Abstract][Full Text] [Related]
17. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
[TBL] [Abstract][Full Text] [Related]
18. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
Hohmann FP; Macklon NS; Fauser BC
J Clin Endocrinol Metab; 2003 Jan; 88(1):166-73. PubMed ID: 12519847
[TBL] [Abstract][Full Text] [Related]
19. A preliminary study on reduced dose (33 or 25 microg) gonadotropin-releasing hormone agonist long protocol for multifollicular ovarian stimulation in patients with high basal serum follicle-stimulating hormone levels undergoing in vitro fertilization-embryo transfer.
Ku SY; Choi YS; Jee BC; Suh CS; Choi YM; Kim JG; Moon SY; Kim SH
Gynecol Endocrinol; 2005 Oct; 21(4):227-31. PubMed ID: 16316845
[TBL] [Abstract][Full Text] [Related]
20. Poor ovarian response to gonadotropin stimulation is associated with low expression of follicle-stimulating hormone receptor in granulosa cells.
Cai J; Lou HY; Dong MY; Lu XE; Zhu YM; Gao HJ; Huang HF
Fertil Steril; 2007 Jun; 87(6):1350-6. PubMed ID: 17296182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
